A Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers

This study has been completed.
Sponsor:
Information provided by:
Prism Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00502346
First received: July 10, 2007
Last updated: August 22, 2008
Last verified: August 2008
  Purpose

The primary objective of the study is to compare the effect of PM101 I.V. administered as an immediate intravenous bolus versus placebo on systolic blood pressure. Secondary objectives include evaluation of change from baseline in heart rate and change from baseline to the lowest value in mean arterial pressure and diastolic pressure.


Condition Intervention Phase
Healthy
Drug: PM10
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Official Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Trial to Determine the Relative Effect of PM101 I.V. Versus Placebo on Hemodynamics in Healthy Adult Volunteers

Further study details as provided by Prism Pharmaceuticals:

Estimated Enrollment: 342
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Be a healthy male or female 18 to 55 years of age, inclusive. Women of childbearing potential must be using a medically acceptable form of birth control for the duration of the trial and must have a negative serum pregnancy test at screening and upon check-in to the study facility.
  • Have a BMI within the range of 18-35 kg/m2.
  • Be able to communicate effectively with the study personnel.
  • Have no significant disease or abnormal laboratory values as determined by medical history, physical examination or laboratory evaluations, conducted at the screening visit or on admission to the clinic.
  • Have a normal 12-lead electrocardiogram, without any clinically significant abnormalities of rate, rhythm or conduction (such as high grade AV block, bifascicular or trifascicular block), and a normal QTc interval (i.e., ≤ 450 msec for males and females).
  • Be a nonsmoker defined as not having smoked in the past 6 months.
  • Be adequately informed of the nature and risks of the study and give written informed consent prior to receiving study medication.

Exclusion Criteria:

  • Known hypersensitivity or allergy to amiodarone, Captisol, Cordarone I.V. or its excipients.
  • Known hypersensitivity or allergy to iodine or radio-opaque dyes.
  • Women who are pregnant or breast feeding.
  • A history or presence of asthma or other pulmonary disease, thyroid disease (hypo- or hyperthyroidism), hepatitis or other liver disease.
  • Any disease or condition (medical or surgical) which, in the opinion of the investigator, might compromise the hematologic, cardiovascular, pulmonary, renal, gastrointestinal, hepatic, or central nervous system; or other conditions that may interfere with the absorption, distribution, metabolism or excretion of study drug, or would place the subject at increased risk.
  • The presence of abnormal laboratory values which are considered clinically significant.
  • Positive screen for Hepatitis B (HbsAg, Hepatitis B Surface Antigen), Hepatitis C (anti HCV, Hepatitis C Antibody), or HIV (anti-HIV 1/2).
  • Received an investigational drug within a period of 30 days prior to enrollment in the study.
  • Received any drug therapy within 2 weeks prior to administration of the first dose of any study-related treatment. This exclusion is extended to 4 weeks for any drugs known to induce or inhibit hepatic drug metabolism. However, women of childbearing potential may receive hormonal contraceptives and the investigator may waive short-term use of a medication, which is not specifically prohibited, if the use occurred more than 5 half-lives prior to the first dose of any study-related treatment.
  • Consumption of alcohol within 48 hours prior to dose administration or during any in-patient period.
  • A positive urine drug screen including ethanol, cocaine, THC, barbiturates, amphetamines, benzodiazepines, and opiates.
  • Any history of alcohol abuse, illicit drug use, significant mental illness, physical dependence to any opioid, or any history of drug abuse or addiction.
  • Prior participation in a Prism Pharmaceuticals amiodarone study.
  • Donation of plasma (500 mL) within 7 days prior to drug administration. Donation or loss of whole blood (excluding the volume of blood that will be drawn during the screening procedures of this study) prior to administration of the study medication as follows: 50 mL to 499 mL of whole blood within 30 days, or more than 499 mL of whole blood within 56 days prior to drug administration.
  • History of severe respiratory failure, circulatory collapse, severe arterial hypotension, heart failure, cardiomyopathy, or sinus node disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00502346

Locations
Canada, Quebec
Anapharm
Montreal, Quebec, Canada
Sponsors and Collaborators
Prism Pharmaceuticals
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00502346     History of Changes
Other Study ID Numbers: 102
Study First Received: July 10, 2007
Last Updated: August 22, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by Prism Pharmaceuticals:
Pharmacodynamics

ClinicalTrials.gov processed this record on September 16, 2014